Lenzing, Trades

Lenzing Trades a Nonbinding Maybe for a EUR 50 Million Certainty

Published on 11/18/2026 at 13:51 | Editorial boerse-global.de
Lenzing commits EUR 27 million to Alabama speciality fibre capacity while reviewing nonbinding offers for its Heiligenkreuz plant, with a 2026 decision deadline.
Lenzing Trades a Nonbinding Maybe for a EUR 50 Million Certainty Illustration mit AI erstellt.

Lenzing's shares slipped 3.4% on Tuesday, a move that had less to do with the Austrian fibre maker than with a broader European pullback after Washington tightened restrictions on AI chip sales to China. Yet the session's real story sits in the gap between two announcements the company made on 12 November — one a firm commitment of capital, the other an invitation to negotiate.

Capital Committed, Suitors Uncommitted

That morning, Lenzing confirmed it will spend EUR 27 million expanding speciality fibre capacity at its Mobile, Alabama site. The outlay forms part of a EUR 50 million programme for the nonwovens business, with the remaining EUR 23 million earmarked for the already-announced build-out at the company's Austrian base in Lenzing.

The same day brought word that several nonbinding purchase offers for the Heiligenkreuz plant have landed on the table and are under review. Lenzing aims to establish by the end of 2026 whether a viable sale can be struck. Failing that, closure at the end of the first quarter of 2027 remains the fallback.

One Plan Is Funded, the Other Is Not

The distinction matters for anyone trying to read the equity. The Alabama and Lenzing spending reflects a decided strategic direction: more capacity in speciality fibres. Heiligenkreuz, by contrast, sits at the mercy of a review whose outcome nobody can yet call.

Should investors sell immediately? Or is it worth buying Lenzing?

Nor does a stack of interested parties guarantee a deal. Multiple approaches raise the odds of a transaction without securing one, and even a signed agreement would only open an alternative to the planned shutdown — its financial worth would depend entirely on the terms. Should the process come up empty, the closure timetable announced in advance takes centre stage again.

By the same token, the investment programme should not be mistaken for proof of commercial success. The figures demonstrate intended capacity growth; whether that translates into improved earnings is a separate question, one that will only be answered as the spending is executed.

Nine-Month Figures Show the Strain

The operating backdrop explains why both tracks are running at once. Over the first nine months of 2026, Lenzing posted adjusted EBITDA of EUR 353 million while recording a net loss of EUR 130.3 million. Early-November disclosure put EBITDA at EUR 316.4 million, a figure that included EUR 36.6 million of restructuring effects, on revenue of EUR 1.93 billion.

Management's full-year guidance points to adjusted EBITDA of EUR 430 million to EUR 460 million.

Lenzing at a turning point? This analysis reveals what investors need to know now.

Deutsche Bank Lifts Its Target

Analysts, for their part, have nudged valuations higher without turning outright bullish. On 9 November, Deutsche Bank raised its price target to EUR 14.30 from EUR 12.70 while keeping a "Hold" rating on the stock.

The calendar now provides the clearest marker: by the end of 2026, Lenzing must show whether the Heiligenkreuz interest can be converted into something binding. Until then, the count of bidders matters far less than the standing the company manages to reach.

Ad

Lenzing Stock: New Analysis - 18 November

Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Lenzing analysis...

Disclaimer...
en | AT0000644505 | LENZING | boerse | 70530959 |